Evidence map›Paper›PMID 33637556›Full record

ReviewHeart (British Cardiac Society)2021

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.

Shruti S Joshi, Trisha Singh, David E Newby, Jagdeep Singh

Erratum issued Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heart (British Cardiac Society), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06012266 (Dose Rationale for Dapagliflozin and Empagliflozin in Paediatric Heart Failure), which is not on this map. Cited by 88 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 8 pooled it
19.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06012266 phase2unknown statusstarted 2024, after this paper: background citation

Dose Rationale for Dapagliflozin and Empagliflozin in Paediatric Heart Failure: a Phase II.a Pharmacokinetics, Ease-of-swallow, Safety and Proof-of-concept Study Among Children 6-18 Years of Age

Ran2024Enrolled12Registered outcomes19Posted comparisons0ConditionsHeart FailureArmsDapagliflozin Tablet, Empagliflozin Tablets
PMID 35948644PMID 17047217PMID 18332283PMID 18988606PMID 21087295PMID 21246352PMID 22633303PMID 24216246PMID 26785826PMID 27812385PMID 29958420PMID 31535829other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 8 syntheses or guidelines pooled it, 176 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Heart failure with preserved ejection fraction: current insights and emerging therapeutic directions.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shruti S JoshiBHF Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, UK sjoshi@ed.ac.uk.ORCID http://orcid.org/0000-0001-9874-6211
Trisha SinghBHF Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0002-4314-9935
David E NewbyBHF Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0001-7971-4628
Jagdeep SinghDepartment of Cardiology, NHS Lothian, Edinburgh, UK.
University of Edinburgh · GBNHS Lothian · GB

Funding

British Heart Foundation FS/CRTF/20/24087Medical Research Council MR/T029153/1Wellcome Trust
6 · The paper itself

Abstract

Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure compared with the healthy population. In recent landmark clinical trials, sodium-glucose co-transporter 2 (SGLT2) inhibitor therapies improve blood glucose control and also reduce cardiovascular events and heart failure hospitalisations in patients with type 2 diabetes. Intriguingly, such clinical benefits have also been seen in patients with heart failure in the absence of type 2 diabetes although the underlying mechanisms are not clearly understood. Potential pathways include improved glycaemic control, diuresis, weight reduction and reduction in blood pressure, but none fully explain the observed improvements in clinical outcomes. More recently, novel mechanisms have been proposed to explain these benefits that include improved cardiomyocyte calcium handling, enhanced myocardial energetics, induced autophagy and reduced epicardial fat. We provide an up-to-date review of cardiac-specific SGLT2 inhibitor-mediated mechanisms and highlight studies currently underway investigating some of the proposed mechanisms of action in cardiovascular health and disease.

Indexed as

heart failureheart failure with reduced ejection fractionpharmacologysystemic review

Identifiers

PMID33637556
PMCPMC8223636
OpenAlexW3131396654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.